Availability and Affordability of Essential Medicines for Diabetes and Catheter Ablation for Atrial Fibrillation with Heart Failure
Added on 2023-06-03
5 Pages1174 Words437 Views
|
|
|
Medicine and Health 1
MEDICINE AND HEALTH
by[Name]
Course
Professor’s Name
Institution
Location of Institution
Date
MEDICINE AND HEALTH
by[Name]
Course
Professor’s Name
Institution
Location of Institution
Date
Medicine and Health 2
Medicine and Health
Article 1
Chow, C.K., Ramasundarahettige, C., Hu, W., AlHabib, K.F., Avezum Jr, A., Cheng, X., Chifamba, J.,
Dagenais, G., Dans, A., Egbujie, B.A. and Gupta, R., 2018. Availability and affordability of
essential medicines for diabetes across high-income, middle-income, and low-income countries:
a prospective epidemiological study. The lancet Diabetes & endocrinology, 6(10), pp.798-808.
The first article seeks to establish if essential medications for diabetes such as insulin
metformin and sulfonylureas available at an affordable price for all people across the world
(Chow et al., 2018 p.798)
From the first article's findings, countries with high incomes levels have high usage of
diabetes medicine as compared to the low income countries. It was also evident that people
from the high-income countries can afford the diabetes drugs as compared to those from middle
and low incomes where most cannot afford the drugs and also readily available. It concluded
that from the low and middle-income countries affordability and availability of diabetes drugs is
very low (Chow et al., 2018 p.802)
The major strengths of the first article were that it was able to establish the reason why
most patients suffering from diabetes type 1 dies within the low and middle-income nations.
The weakness of the study was that it only considered the essential diabetes drugs and
excluded the costs for new drugs. Additionally, during the data collection; there was no
distinction between the type 1 and type 2 diabetes. Another weakness was that the study did
not examine if the patient were on any other medication which diabetes patient may be taking
thus affecting the ability to afford the drugs (Htun, et al., 2015 p.5) The contribution of this paper
in relation to readiness and affordability for diabetes drugs is that it helps organizations such as
WHO, determine those countries where diabetes drugs are not affordable and available and
offer their aid.
Medicine and Health
Article 1
Chow, C.K., Ramasundarahettige, C., Hu, W., AlHabib, K.F., Avezum Jr, A., Cheng, X., Chifamba, J.,
Dagenais, G., Dans, A., Egbujie, B.A. and Gupta, R., 2018. Availability and affordability of
essential medicines for diabetes across high-income, middle-income, and low-income countries:
a prospective epidemiological study. The lancet Diabetes & endocrinology, 6(10), pp.798-808.
The first article seeks to establish if essential medications for diabetes such as insulin
metformin and sulfonylureas available at an affordable price for all people across the world
(Chow et al., 2018 p.798)
From the first article's findings, countries with high incomes levels have high usage of
diabetes medicine as compared to the low income countries. It was also evident that people
from the high-income countries can afford the diabetes drugs as compared to those from middle
and low incomes where most cannot afford the drugs and also readily available. It concluded
that from the low and middle-income countries affordability and availability of diabetes drugs is
very low (Chow et al., 2018 p.802)
The major strengths of the first article were that it was able to establish the reason why
most patients suffering from diabetes type 1 dies within the low and middle-income nations.
The weakness of the study was that it only considered the essential diabetes drugs and
excluded the costs for new drugs. Additionally, during the data collection; there was no
distinction between the type 1 and type 2 diabetes. Another weakness was that the study did
not examine if the patient were on any other medication which diabetes patient may be taking
thus affecting the ability to afford the drugs (Htun, et al., 2015 p.5) The contribution of this paper
in relation to readiness and affordability for diabetes drugs is that it helps organizations such as
WHO, determine those countries where diabetes drugs are not affordable and available and
offer their aid.
End of preview
Want to access all the pages? Upload your documents or become a member.